Evidence favouring the efficacy of convalescent plasma for COVID-19 therapy

Michael J. Joyner^{1*}, Stephen A. Klassen¹, Jonathon W. Senefeld¹, Patrick W. Johnson², Rickey E. Carter², Chad C. Wiggins¹, Shmuel Shoham³, Brenda J. Grossman⁴, Jeffrey P. Henderson^{5,6}, James Musser^{7,8,9}, Eric Salazar^{7,9}, William R. Hartman¹⁰, Nicole M. Bouvier^{11,12}, Sean T. H. Liu^{11,12}, Liise-anne Pirofski¹³, Sarah E. Baker¹, Noud van Helmond¹⁴, R. Scott Wright^{15,16}, DeLisa Fairweather¹⁷, Katelyn A. Bruno¹⁷, Nigel S. Paneth^{18,19}, and Arturo Casadevall²⁰

Affiliations:

⁵Division of Infectious Diseases, Department of Medicine and ⁶Department of Molecular Microbiology, Washington University School of Medicine in St. Louis, St. Louis, Missouri, USA. ⁷Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, Texas ⁸Center for Molecular and Translational Human Infectious Diseases, Houston Methodist Research Institute, Houston, Texas

*Correspondence:

Michael J. Joyner, M.D., Department of Anesthesiology and Perioperative Medicine Mayo Clinic | 200 First Street SW | Rochester, MN 55905 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |

¹Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, Minnesota,

²Department of Health Sciences Research, Mayo Clinic, Jacksonville, Florida,

³Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland,

⁴Department of Pathology and Immunology, Washington University School of Medicine in St. Louis, St. Louis, Missouri,

⁹Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, New York

¹⁰Department of Anesthesiology, University of Wisconsin-Madison School of Medicine and Public Health

¹¹Division of Infectious Diseases, Department of Medicine and ¹²Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York

¹³Division of Infectious Diseases, Department of Medicine, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York

¹⁴Department of Anesthesiology, Cooper Medical School of Rowan University, Cooper University Health Care, Camden, New Jersey

¹⁵Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota

¹⁶Director Human Research Protection Program, Mayo Clinic, Rochester, Minnesota

¹⁷Department of Cardiovascular Medicine, Mayo Clinic, Jacksonville, Florida

¹⁸Department of Epidemiology and Biostatistics and ¹⁹Department of Pediatrics and Human Development, College of Human Medicine, Michigan State University, East Lansing, Michigan ²⁰Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland

Abstract

To determine the effect of COVID-19 convalescent plasma on mortality, we aggregated patient outcome data from randomized clinical trials, matched control, case series, and case report studies. Fixed-effects analyses demonstrated that hospitalized COVID-19 patients transfused with convalescent plasma exhibited a \sim 57% reduction in mortality rate (10%) compared to matched-patients receiving standard treatments (22%; OR: 0.43, P < 0.001). These data provide evidence favouring the efficacy of human convalescent plasma as a therapeutic agent in hospitalized COVID-19 patients.

Brief Communication

Convalescent plasma is a century-old passive antibody therapy that has been used to treat outbreaks of novel infectious diseases, including those affecting the respiratory system^{1,2}. Due to the lack of vaccines or monoclonal antibody therapies, human convalescent plasma is currently being used wordwide to treat coronavirus disease 2019 (COVID-19), which is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)²⁻⁵. However, evidence for therapeutic COVID-19 convalescent plasma efficacy still requires definitive support from large randomized clinical trials (RCT). As a result, there remains a lack of consensus on convalescent plasma use in hospitalized COVID-19 patients⁶. Smaller RCTs, matched-control studies, and case series studies investigating convalescent plasma therapy for COVID-19 have emerged and provided a positive efficacy signal⁷⁻²⁷. Most of these studies, however, lacked appropriate statistical power or were terminated early.

There is an urgent need to determine the efficacy of potential treatments amidst the ongoing COVID-19 pandemic. Thus, we used a practical approach to pool patient cohort data from RCTs, matched control, and case series or case report studies in real time. Our primary objective was to derive an aggregate estimate of mortality rates from case and control cohorts of contemporaneous COVID-19 studies.

Studies published on pre-print servers or peer-reviewed journals that investigated human convalescent plasma therapy among hospitalized COVID-19 patients were identified from a search of the online PubMed database through August 25, 2020. Keywords used in the search included: ((convalescent plasma) OR (convalescent serum)) AND COVID-19 using the following limits: Humans. The references of all eligible studies were also reviewed to identify other potentially eligible studies. In order to be considered eligible for inclusion, studies must have: 1) included hospitalized patients with COVID-19, 2) used convalescent plasma treatment, and 3) reported mortality.

Mortality rates were calculated at the longest reported vital status for each study and compared between cohorts using odds ratios (OR) determined by fixed effect meta-analysis models. Fixed effect meta-regression analyses evaluated the contribution of moderator variables (i.e., mean or median cohort age, proportion of cohort receiving mechanical ventilation, and duration of study follow up) on the aggregate OR computed for all controlled studies. All analyses were performed with Comprehensive Meta-analysis Software (Biostat, version 3.3.070). Tests were two-tailed and alpha was 0.05.

The literature search yielded 113 studies, of which 21 studies met the eligibility criteria. The present analyses included a total of twelve controlled studies including two RCTs and 9 case series or case reports containing 4,173 COVID-19 patient outcomes^{7–27} from around the world (**Table 1**). The mean or median age of patients enrolled in these studies ranged from 52 to 70 years, with a greater proportion of men than women in most studies (proportion of women: 0% to 53%). All studies included patients with severe or life-threatening COVID-19. At the time of plasma transfusion, the proportion of patients on mechanical ventilation varied by study from 0% to 81%. The duration of follow up ranged from 7 to 30 days. The mortality rates for COVID-19 patients transfused with convalescent plasma in case series or case reports ranged from 0% to 20%. Among controlled studies, patients transfused with convalescent plasma exhibited a reduced mortality rate (10%) compared to non-transfused COVID-19 patients (22%; OR: 0.43, *P* < 0.001). The aggregate OR of 0.43 indicates that convalescent plasma was associated with a 57% reduction in the odds of mortality among hospitalized COVID-19 patients. Meta-regression analysis indicated that mean or median cohort age, proportion of cohort receiving mechanical

ventilation, and duration of study follow up did not affect the aggregate OR computed for all controlled studies (all coefficients P > 0.24). Both Fixed and Random effects models provided similar results for the aggregate OR and meta-regression.

In this outcomes analysis of contemporaneous COVID-19 convalescent plasma studies, the aggregate mortality rate of transfused COVID-19 patients was substantially lower than that of non-transfused COVID-19 patients. These results favour the efficacy of convalescent plasma as a COVID-19 therapeutic agent. The primary biological hypothesis for the efficacy of convalescent plasma is antibody-mediated SARS-CoV-2 viral neutralization and interference with viral replication, though other biological mechanisms may also contribute to the mitigation of symptoms². These results align with similar analyses of historical data from convalescent plasma trials for viral diseases such as the 1918 flu epidemic¹, Severe acute respiratory syndrome²⁸, and H1N1 influenza²⁹.

There are several limitations to this analysis including aggregating mortality data across study populations that varied by: 1) the nation of data origin, 2) timing relative to worldwide progression of the pandemic, 3) clinical diagnostic and treatment algorithms, 4) plasma antibody titer and administration volume, 5) the latency between COVID-19 diagnosis and transfusion and 6) the duration of follow up after transfusion. We note that the reports cited in **Table 1** include positive results from different countries, suggesting that efficacy is robust across different health systems. Given the safety of plasma administration in COVID-19 patients^{3,4}, the results of this real-time data aggregration provide encouragement for its continued used as a therapy and may have broad implications for the treatment of COVID-19 and design of RCTs. Importantly, many of the patients enrolled in the studies included in the present analyses received convalescent plasma transfusions later in their disease course. In this context, prior to antibiotics and effective vaccinations, convalescent plasma therapy for streptococcal pneumonia and bacterial meningitis was widely understood to be most efficaceous very early in the course of hospitalizations^{2,30}. As a result, our analysis may underestimate the mortality reduction acheivable through early administration of convalescent plasma for COVID-19.

References

- 1. Luke, T. C., Kilbane, E. M., Jackson, J. L. & Hoffman, S. L. Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? *Ann. Intern. Med.* **145**, 599–609 (2006).
- 2. Casadevall, A. & Pirofski, L. The convalescent sera option for containing COVID-19. *J. Clin. Invest.* **130**, 1545–1548 (2020).
- 3. Joyner, M. J. *et al.* Safety Update: COVID-19 Convalescent Plasma in 20,000 Hospitalized Patients. *Mayo Clin. Proc.* **95**, (2020).
- 4. Joyner, M. *et al.* Early Safety Indicators of COVID-19 Convalescent Plasma in 5,000 Patients. *J. Clin. Invest.* (2020).
- 5. Bloch, E. M. *et al.* Deployment of convalescent plasma for the prevention and treatment of COVID-19. *J. Clin. Invest.* (2020).
- 6. Piechotta, V. *et al.* Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review. *Cochrane Database Syst. Rev.* (2020).
- 7. Li, L. *et al.* Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial. *JAMA* (2020).
- 8. Gharbharan, A. *et al.* Convalescent Plasma for COVID-19. A randomized clinical trial. *medRxiv* (2020).
- 9. Zeng, Q.-L. *et al.* Effect of convalescent plasma therapy on viral shedding and survival in patients with coronavirus disease 2019. *J. Infect. Dis.* **222**, 38–43 (2020).
- 10. Donato, M. *et al.* Clinical and laboratory evaluation of patients with SARS-CoV-2 pneumonia treated with high-titer convalescent plasma: a prospective study. *medRxiv* (2020).
- 11. Salazar, E. *et al.* Treatment of COVID-19 Patients with Convalescent Plasma Reveals a Signal of Significantly Decreased Mortality. *Am. J. Pathol.* (2020).
- 12. Xia, X. *et al.* Improved Clinical Symptoms and Mortality on Severe/Critical COVID-19 Patients Utilizing Convalescent Plasma Transfusion. *Blood* (2020).
- 13. Zhang, B. *et al.* Treatment with convalescent plasma for critically ill patients with SARS-CoV-2 infection. *Chest* (2020).
- 14. Ahn, J. Y. *et al.* Use of convalescent plasma therapy in two COVID-19 patients with acute respiratory distress syndrome in Korea. *J. Korean Med. Sci.* **35**, (2020).
- 15. Bobek, I. *et al.* Successful administration of convalescent plasma in critically ill COVID-19 patients in Hungary: the first two cases. *Orv. Hetil.* **161**, 1111–1121 (2020).
- 16. Im, J. H., Nahm, C. H., Baek, J. H., Kwon, H. Y. & Lee, J.-S. Convalescent plasma therapy in coronavirus disease 2019: a case report and suggestions to overcome obstacles. *J. Korean Med. Sci.* **35**, (2020).
- 17. Peng, H. *et al.* A synergistic role of convalescent plasma and mesenchymal stem cells in the treatment of severely ill COVID-19 patients: a clinical case report. *Stem Cell Res. Ther.* **11**, 1–6 (2020).
- 18. Xu, T., Lin, B., Chen, C., Liu, L. & Xue, Y. Non-optimal effectiveness of convalescent plasma transfusion and hydroxychloroquine in treating COVID-19: a case report. *Virol. J.* **17**, 1–3 (2020).
- 19. Rasheed, A. M. *et al.* The therapeutic effectiveness of Convalescent plasma therapy on treating COVID-19 patients residing in respiratory care units in hospitals in Baghdad, Iraq. *medRxiv* (2020).
- 20. Olivares-Gazca, J. C. *et al.* Infusion of convalescent plasma is associated with clinical improvement in critically ill patients with COVID-19: a pilot study. *Rev Invest Clin* **72**, 159–164 (2020).

- 21. Hegerova, L. *et al.* Use of Convalescent Plasma in Hospitalized Patients with Covid-19-Case Series. *Blood* (2020).
- 22. Liu, S. T. H. *et al.* Convalescent plasma treatment of severe COVID-19: A matched control study. *medRxiv* (2020).
- 23. Perotti, C. *et al.* Mortality reduction in 46 severe Covid-19 patients treated with hyperimmune plasma. A proof of concept single arm multicenter interventional trial. *medRxiv* (2020).
- 24. Abolghasemi, H. *et al.* Clinical Efficacy of Convalescent Plasma for Treatment of COVID-19 Infections: Results of a Multicenter Clinical Study. *Transfus. Apher. Sci.* 102875 (2020).
- 25. Hartman, W., Hess, A. S. & Connor, J. P. Hospitalized COVID-19 patients treated with Convalescent Plasma in a mid-size city in the midwest. *medRxiv* (2020).
- 26. Duan, K. *et al.* Effectiveness of convalescent plasma therapy in severe COVID-19 patients. *Proc. Natl. Acad. Sci.* **117**, 9490–9496 (2020).
- 27. Martinez-Resendez, M. F. *et al.* Initial experience in Mexico with convalescent plasma in COVID-19 patients with severe respiratory failure, a retrospective case series. *medRxiv* (2020).
- 28. Cheng, Y. *et al.* Use of convalescent plasma therapy in SARS patients in Hong Kong. *Eur. J. Clin. Microbiol. Infect. Dis.* **24**, 44–46 (2005).
- 29. Hung, I. F. N. *et al.* Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. *Clin. Infect. Dis.* **52**, 447–456 (2011).
- 30. Casadevall, A. & Scharff, M. D. Return to the past: the case for antibody-based therapies in infectious diseases. *Clin. Infect. Dis.* **21**, 150–161 (1995).

Acknowledgements: The authors express their gratitude to convalescent plasma donors.

Author contributions: MJJ, REC, AC, NSP conceived and designed the study. MJJ, SAK, JWS, PWJ, CCW, REC analyzed the data and performed statistical analyses. All authors reviewed, critically revised and approved the final version of the manuscript.

Competing Interests: The authors declare no competing interests.

Data availability: The data supporting the study findings are available within the paper.

Table

Study	Location	Convalescent Plasma			Control			Statistics	
		Survivor	Non-Survivor	Mortality	Survivor	Non-Survivor	Mortality	OR	Р
Controlled Studies									
Duan et al. 26	CHN	10	0	0%	7	3	30%	0.10	0.15
Rasheed et al. 19	IRQ	20	1	5%	20	8	29%	0.13	0.06
Perotti et al. 23	ITA	43	3	7%	16	7	30%	0.16	0.0
Hegerova et al. 21	Washington, USA	18	2	10%	14	6	30%	0.26	0.13
Zeng et al. 9	CHN	1	5	83%	1	14	93%	0.36	0.50
Donato et al. 10	New York, USA	36	11	23%	775	565	42%	0.42	0.0
Liu et al. 22	New York, USA	35	5	13%	118	38	24%	0.44	0.1
Salazar et al. 11	Texas, USA	131	5	4%	232	19	8%	0.47	0.14
Gharbharan et al. 8	NLD	37	6	14%	32	11	26%	0.47	0.1
Xia et al. 12	CHN	135	3	2%	1371	59	4%	0.52	0.2
Abolghasemi et al. 24	IRN	98	17	15%	56	18	24%	0.54	0.10
Li et al. 7	CHN	43	8	16%	38	12	24%	0.59	0.30
Fixed Effect Model ^a		607	66	10%	2680	760	22%	0.43	< 0.0
Case Series or Reports									
Martinez-Resendez et al. 27	MEX	8	0	0%					
Zhang et al. 13	CHN	4	0	0%					
Ahn et al. 14	KOR	2	0	0%					
Bobek et al. 15	HUN	2	0	0%					
Im et al. 16	KOR	1	0	0%					
Peng et al. 17	CHN	1	0	0%					
Xu et al. 18	CHN	1	0	0%					
Hartman et al. 25	Wisconsin, USA	27	4	13%					
Olivares-Gazca et al. 20	MEX	8	2	20%					
Total		54	6	10%					

OR, odds ratio

^a Relative weight (%): Duan et al. (1.1), Rasheed et al. (2.2), Perotti et al. (4.7), Hegerova et al. (3.4), Zeng et al. (1.2), Donato et al. (22.0), Liu et al. (10.1), Salazar et al. (10.1), Gharbharan et al. (8.5), Xia et al. (7.5), Abolghasemi et al. (18.8), Li et al. (10.4).

Figure legend

Figure 1. The impact of human convalescent plasma therapy on COVID-19 patient mortality. Forest plot illustrating odds ratios (OR) and 95% confidence intervals for controlled studies and aggregate fixed effect models. Fixed effect ORs for Duan et al.²⁶, Rasheed et al.¹⁹, Perotti et al.²³, Hegerova et al.²¹, Zeng et al.⁹, Donato et al.¹⁰, Liu et al.²², Salazar et al.¹¹, Gharbharan et al.⁸, Xia et al.¹², Abolghasemi et al.²⁴, and Li et al.⁷ are represented in blue. The aggregate fixed effect model OR is represented in shaded blue.

Figure

